Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Accumulated Expenses (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Accumulated Expenses data on record, last reported at $17.8 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 7.65% year-over-year to $17.8 million; the TTM value through Dec 2025 reached $17.8 million, up 7.65%, while the annual FY2025 figure was $17.8 million, 7.65% up from the prior year.
  • Accumulated Expenses reached $17.8 million in Q4 2025 per TNGX's latest filing, up from $3.2 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $17.8 million in Q4 2025 and bottomed at $202089.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $9.6 million, with a median of $10.0 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: soared 13312.37% in 2021, then tumbled 76.88% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $9.9 million in 2021, then plummeted by 41.96% to $5.7 million in 2022, then decreased by 5.63% to $5.4 million in 2023, then skyrocketed by 204.65% to $16.5 million in 2024, then rose by 7.65% to $17.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $17.8 million in Q4 2025, $3.2 million in Q1 2025, and $16.5 million in Q4 2024.